Thursday, July 26, 2012
Blocking IL-7 in type 1 diabetes.
Lee et al. and Penaranda et al. have evidence that blocking IL-7 signaling can
protect against type 1 diabetes.
normally engages the T cell membrane-associated IL-7 receptor (IL-7R; CD127) [b],
leading to T cell proliferation and activity [c]. High T cell levels due
to IL-7 signaling lead to potent immune activity against pathogens, but mutations
thought to activate this pathway are linked with autoimmune disease [d].
mAbs independently discovered by Pfizer Inc. and by
researchers at the University of California, San Francisco block IL-7
signaling and arrest the progression of type 1 diabetes in mice. Effimune S.A.S.
has the anti-IL-7R mAb MD707 in preclinical
development for transplant rejection and a range of autoimmune indications.